# Phase 1 Amyotrophic Lateral Sclerosis trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials in phase 1 for Amyotrophic Lateral Sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Amyotrophic Lateral Sclerosis trials: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/amyotrophic-lateral-sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906665 | A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Sachi Bioworks Inc. | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906665) |
| October 20, 2026 | NCT07883590 | A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). | Eli Lilly and Company | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883590) |
| October 15, 2026 | NCT07875972 | Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875972) |
| September 24, 2026 | NCT07838389 | Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | ALS - Amyotrophic Lateral Sclerosis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838389) |
| May 15, 2026 | NCT07589764 | Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS | Duke University | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis ALS | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589764) |
| May 6, 2026 | NCT07571200 | A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) | Eli Lilly and Company | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571200) |
| May 6, 2026 | NCT07571174 | A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | Eli Lilly and Company | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571174) |
| February 10, 2026 | NCT07401121 | Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis | Celosia Therapeutics Pty Ltd | Phase 1 | Recruiting | ALS (Amyotrophic Lateral Sclerosis) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07401121) |
| December 17, 2025 | NCT07290062 | A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic... | Insmed Gene Therapy LLC | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07290062) |
| October 27, 2025 | NCT07221240 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis | PRG Science & Technology Co., Ltd. | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221240) |
| October 3, 2025 | NCT07204977 | Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204977) |
| August 12, 2025 | NCT07118319 | The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral... | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis (ALS) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07118319) |
| August 3, 2025 | NCT07100119 | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | Eli Lilly and Company | Phase 1 | Recruiting | ALS (Amyotrophic Lateral Sclerosis) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100119) |
| July 30, 2025 | NCT07093268 | Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis | Brain Trust Bio | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093268) |
| November 26, 2024 | NCT06704347 | Safety Study of XT-150 in Participants With ALS | Xalud Therapeutics, Inc. | Phase 1 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06704347) |
| November 4, 2024 | NCT06671236 | Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases | Novabio Therapeutics | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis (ALS) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06671236) |
| October 30, 2024 | NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Amylyx Pharmaceuticals Inc. | Phase 1 | Recruiting | ALS | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06665165) |
| September 23, 2024 | NCT06607900 | hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases | Xuanwu Hospital, Beijing | Phase 1 | Not yet recruiting | Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy, Fronto-temporal Dementia... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607900) |
| August 16, 2024 | NCT06556394 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral... | Ractigen Therapeutics. | Phase 1 | Recruiting | Amyotrophic Lateral Sclerosis | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06556394) |
| August 16, 2023 | NCT05995782 | A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 | 1ST Biotherapeutics, Inc. | Phase 1 | Recruiting | Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05995782) |
| December 14, 2020 | NCT04667013 | A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN | Guangzhou Magpie Pharmaceuticals Co., Ltd. | Phase 1 | Not yet recruiting | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04667013) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 4 |
| Ractigen Therapeutics. | 1 |
| Duke University | 1 |
| PRG Science & Technology Co., Ltd. | 1 |
| 1ST Biotherapeutics, Inc. | 1 |
| Insmed Gene Therapy LLC | 1 |
| Sachi Bioworks Inc. | 1 |
| Xalud Therapeutics, Inc. | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Brain Trust Bio | 1 |
| Xuanwu Hospital, Beijing | 1 |
| Amylyx Pharmaceuticals Inc. | 1 |
| XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 1 |
| Guangzhou Magpie Pharmaceuticals Co., Ltd. | 1 |
| Novabio Therapeutics | 1 |
| Celosia Therapeutics Pty Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 9 |
| Canada | 5 |
| China | 4 |
| Belgium | 3 |
| Germany | 3 |
| Netherlands | 3 |
| Spain | 3 |
| Australia | 2 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
- [Indo Chinese restaurants in the United States](https://specstream.ai/data/businesses/indo-chinese-restaurants/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
- [Cabinet makers in the United States](https://specstream.ai/data/businesses/cabinet-makers/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
